Nephros (NEPH) Competitors $3.99 -0.16 (-3.86%) Closing price 03:59 PM EasternExtended Trading$4.04 +0.04 (+1.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. MBOT, ELMD, BSGM, PDEX, LNSR, LAKE, AVR, PROF, LUCD, and ZJYLShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Microbot Medical (MBOT), Electromed (ELMD), Biosig Technologies (BSGM), Pro-Dex (PDEX), LENSAR (LNSR), Lakeland Industries (LAKE), Anteris Technologies Global (AVR), Profound Medical (PROF), Lucid Diagnostics (LUCD), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors Microbot Medical Electromed Biosig Technologies Pro-Dex LENSAR Lakeland Industries Anteris Technologies Global Profound Medical Lucid Diagnostics Jin Medical International Microbot Medical (NASDAQ:MBOT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Do analysts prefer MBOT or NEPH? Microbot Medical currently has a consensus target price of $9.00, suggesting a potential upside of 167.06%. Nephros has a consensus target price of $5.50, suggesting a potential upside of 37.84%. Given Microbot Medical's higher probable upside, equities analysts clearly believe Microbot Medical is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Microbot Medical 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Nephros 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MBOT or NEPH more profitable? Nephros has a net margin of 7.95% compared to Microbot Medical's net margin of 0.00%. Nephros' return on equity of 14.89% beat Microbot Medical's return on equity.Company Net Margins Return on Equity Return on Assets Microbot MedicalN/A -76.27% -67.54% Nephros 7.95%14.89%11.64% Which has higher earnings and valuation, MBOT or NEPH? Nephros has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMicrobot MedicalN/AN/A-$11.44M-$0.58-5.81Nephros$14.16M2.99$70K$0.1233.25 Does the media refer more to MBOT or NEPH? In the previous week, Microbot Medical and Microbot Medical both had 2 articles in the media. Microbot Medical's average media sentiment score of -0.12 beat Nephros' score of -0.13 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nephros 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, MBOT or NEPH? Microbot Medical has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Do institutionals & insiders hold more shares of MBOT or NEPH? 16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryNephros beats Microbot Medical on 12 of the 14 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.99M$10.94B$5.76B$9.85BDividend YieldN/A1.85%6.71%4.51%P/E Ratio33.2514.7559.1122.53Price / Sales2.9931.25547.00119.09Price / Cash207.3924.5637.0558.92Price / Book4.933.5710.916.06Net Income$70K$212.34M$3.29B$266.28M7 Day Performance-0.99%-3.31%0.01%-0.76%1 Month Performance23.15%7.76%7.06%3.83%1 Year Performance111.11%-8.09%50.09%24.39% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.5421 of 5 stars$3.99-3.9%$5.50+37.8%+121.3%$43.99M$14.16M33.2530Positive NewsShort Interest ↑Gap DownMBOTMicrobot Medical2.0293 of 5 stars$4.04-3.0%$9.00+123.0%+306.9%$184.20MN/A-6.9720ELMDElectromed3.0612 of 5 stars$20.91+3.5%$33.50+60.2%+39.4%$175.31M$61.44M27.87160BSGMBiosig Technologies1.6481 of 5 stars$5.30+0.1%$10.00+88.6%+970.5%$166.68M$40K0.0050PDEXPro-Dex2.5148 of 5 stars$46.25+0.1%$56.00+21.1%+108.1%$150.78M$53.84M16.52140News CoverageEarnings ReportLNSRLENSAR1.0747 of 5 stars$12.57-0.7%$15.00+19.4%+160.0%$150.08M$58.36M-2.99110Positive NewsLAKELakeland Industries4.6957 of 5 stars$15.45+0.6%$26.00+68.3%-38.0%$146.88M$167.21M-5.132,100News CoverageAVRAnteris Technologies Global2.1274 of 5 stars$3.84+3.8%$16.50+329.7%N/A$138.47M$2.70M0.00138News CoveragePROFProfound Medical2.3859 of 5 stars$4.61-1.4%$11.00+138.9%-49.8%$138.39M$11.84M-3.15150LUCDLucid Diagnostics2.7576 of 5 stars$1.19+2.2%$3.55+199.6%+53.1%$128.55M$4.35M-1.0070ZJYLJin Medical InternationalN/A$0.78-8.8%N/A-76.3%$122.11M$23.50M0.00245Gap Down Related Companies and Tools Related Companies Microbot Medical Competitors Electromed Competitors Biosig Technologies Competitors Pro-Dex Competitors LENSAR Competitors Lakeland Industries Competitors Anteris Technologies Global Competitors Profound Medical Competitors Lucid Diagnostics Competitors Jin Medical International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
